Positron emission tomography quantification of serotonin transporter binding in medication-free bipolar disorder.

Autor: Miller JM; Division of Molecular Imaging and Neuropathology, New York State Psychiatric Institute, New York, New York.; Department of Psychiatry, Columbia University, New York, New York., Everett BA; Division of Molecular Imaging and Neuropathology, New York State Psychiatric Institute, New York, New York., Oquendo MA; Division of Molecular Imaging and Neuropathology, New York State Psychiatric Institute, New York, New York.; Department of Psychiatry, Columbia University, New York, New York., Ogden RT; Division of Molecular Imaging and Neuropathology, New York State Psychiatric Institute, New York, New York.; Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, New York., Mann JJ; Division of Molecular Imaging and Neuropathology, New York State Psychiatric Institute, New York, New York.; Department of Psychiatry, Columbia University, New York, New York., Parsey RV; Department of Psychiatry and Behavioral Science, Stony Brook University School of Medicine, Stony Brook, New York.
Jazyk: angličtina
Zdroj: Synapse (New York, N.Y.) [Synapse] 2016 Jan; Vol. 70 (1), pp. 24-32. Date of Electronic Publication: 2015 Oct 19.
DOI: 10.1002/syn.21868
Abstrakt: Objectives: Bipolar disorder (BD) is associated with abnormalities in the serotonin transporter (5-HTT), but specific in vivo findings have been discrepant. Using positron emission tomography (PET) and [(11)C]DASB, we compared 5-HTT binding between unmedicated depressed BD subjects and healthy volunteers (HVs).
Experimental Design: 5-HTT binding in six brain regions was compared between 17 depressed, unmedicated BD subjects and 31 HVs, using the outcome measure of VT/fP (proportional to the total number of available transporters). Alternative outcome measures were examined as well. 47% of BD were BP I; and 65% reported a prior suicide attempt.
Principal Observations: 5-HTT binding (VT/fP ) did not differ between BD and HV groups considering six brain regions of interest simultaneously (P = 0.24). In contrast, alternative outcome measures (BPF*, BPP*, and BPND*) indicated lower binding in BD compared with HV across these six regions of interest (BPF*: P = 0.047; BPP*: P = 0.032; BPND*: P = 0.031). 5-HTT binding was unrelated to suicide attempt history, depression severity, bipolar subtype, or history of past substance use disorder.
Conclusions: Choice of outcome measure strongly affects comparisons of serotonin transporter binding using PET with [(11)C]DASB. We do not find evidence of abnormal 5-HTT binding in bipolar depression using our primary outcome measure, VT /fP . However, we did observe lower 5-HTT binding in BD with alternative outcome measures that are frequently used with [(11)C]DASB. Relative merits and assumptions of different outcome measures are discussed. Evaluation in larger samples and during different mood states, including remission, is warranted.
(© 2015 Wiley Periodicals, Inc.)
Databáze: MEDLINE
Externí odkaz: